Misbranded vs. Adulterated Under the FDCA: A Plain-Language Primer

Two Words That Don't Mean the Same Thing

Spend any time reading FDA correspondence — warning letters, import alerts, guidance documents — and two words turn up constantly: adulterated and misbranded. Almost everyone who isn't a regulatory attorney uses them interchangeably. They aren't interchangeable. One is a verdict on the material in the container; the other is a verdict on the words printed around it. Every compound discussed on this site is supplied for research use only, and this article is a primer on statutory vocabulary, not guidance for any human application.

Knowing which of the two a document alleges tells you what kind of problem is on the table — and what would actually fix it. Below: the two sections of the Federal Food, Drug, and Cosmetic Act that define them, why "labeling" is a bigger category than most readers assume, how intended use gets decided, and where a research-use-only statement fits.

Two Questions, Two Sections of the FDCA

The short version: the statute asks two separate questions, and it answers them in two separate places. Is the material what it is represented to be? That's adulteration. Do the words tell the truth? That's misbranding.

The split has a history. The FDCA was enacted in 1938 after the elixir sulfanilamide disaster, in which more than a hundred people died because a manufacturer had dissolved an antibiotic in diethylene glycol, a poisonous solvent. Nothing on that bottle was false; the composition was the failure. That's a large part of why the Act's composition provisions ask whether a substance may render a product injurious rather than waiting for proof that it did.

For drugs, the geography is simple. Section 501 of the Act (21 U.S.C. 351) covers adulterated drugs and devices, and section 502 (21 U.S.C. 352) covers misbranded ones. They sit next to each other in Chapter V, Part A, and they're written to be read independently.

FDA's own shorthand is about as plain as regulatory language gets. The agency describes adulteration as concerning product composition — ingredients, contaminants, processing, packaging, or handling — and misbranding as concerning improperly labeled or deceptively packaged products. Adulteration means something is wrong with the thing. Misbranding means something is wrong with the account of the thing.

One structural point surprises people: Chapter III, which sets out the prohibited acts, operates on a strict-liability standard. Intent is not an element of the offense — a reading courts upheld in United States v. Dotterweich and United States v. Park.

Adulterated: When the Problem Is the Material Itself

Adulteration is a judgment about the substance, and it can be reached without reading a single word of marketing copy.

The composition grounds

The grounds fall into recognizable families. A product is adulterated if it bears or contains a poisonous or deleterious substance that may render it injurious under the conditions of use stated in its labeling or under customary use; if it consists in whole or in part of a filthy, putrid, or decomposed substance; or if its container is itself composed of a deleterious substance. FDA's glossary compresses the category into four adjectives: defective, unsafe, filthy, or produced under insanitary conditions.

A quieter ground matters more in practice for synthetic material: strength, quality, or purity differing from what the labeling represents. That's where an analytical result stops being an internal QC number and becomes a statutory question. If a certificate says 98% and the material is 91%, that gap is exactly what the adulteration provisions were written to capture. For what those numbers mean line by line, see our walkthrough on reading a certificate of analysis field by field.

The process grounds

This next part reads as backwards until the logic clicks. Under section 501(a)(2)(B), a drug is adulterated if it wasn't manufactured in conformity with current good manufacturing practice requirements — and that holds even if no contaminant is ever detected in the finished material. A facility with no environmental monitoring records, no validated cleaning procedure, and no stability program can turn out a perfectly clean batch and still be making adulterated product, because the statute locates the hazard in the uncontrolled process itself.

The insanitary-conditions ground works the same way, asking whether a product was prepared, packed, or held under conditions whereby it may have become contaminated — not whether contamination occurred. The burden sits on demonstrable control, which is why inspections generate so much discussion of documentation rather than test results. Adulteration findings are built out of facilities, records, and analytical data.

Misbranded: When the Problem Is What the Label Says

Misbranding is a judgment about representations. A product with impeccable chemistry, made in an immaculate facility, can still be misbranded.

False, misleading, or simply incomplete

The central prohibition is labeling that is "false or misleading in any particular." Alongside it sit mechanical requirements — the name and place of business of the manufacturer, packer, or distributor, and an accurate statement of quantity — plus a conspicuousness requirement that's easy to overlook: required information must be placed so prominently and in such terms "as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use." Technically present but functionally buried doesn't satisfy the statute.

Then there's section 201(n), the provision most often missed on a first reading. Whether labeling is misleading turns not only on what it says but on the extent to which it fails to reveal facts material in light of the representations made. An omission can misbrand a product.

Adequate directions for use — section 502(f)(1)

Section 502(f)(1) requires that labeling bear adequate directions for use, and 21 CFR 201.5 reads that phrase as directions under which a layperson can use the product safely for its intended purposes.

That definition is why 502(f)(1) is the most-cited misbranding theory in agency letters to chemical suppliers, and the reasoning is tighter than it first appears. In its February 2025 letter to USApeptide.com, FDA reasoned that products intended for conditions "not amenable to self-diagnosis and treatment by a layperson" cannot carry adequate lay directions as a matter of logic. So no adequate directions can exist — and their absence is itself the violation. A seller can't write their way out of that one; the premise of the intended use forecloses it.

Other routes are mechanical: failing to register a facility or list a drug with FDA, or offering a prescription drug without requiring a prescription.

Why "Labeling" Means More Than the Sticker on the Vial

Most misbranding findings trace back to a single definitional fact that catches people off guard: in the FDCA, "labeling" is a far larger category than the label.

The definition reaches all labels and other written, printed, or graphic matter on the product, on its containers or wrappers, or accompanying it — and FDA has long read "accompanying" functionally rather than physically. Product pages, specification sheets, FAQ copy, and promotional email all get quoted back as labeling. Nothing needs to be printed on the vial to count.

That breadth connects directly to how intended use is determined. Under 21 CFR 201.128, intended use turns on the objective intent of the persons responsible for the labeling, established by their own expressions or by the circumstances surrounding distribution — not on what the seller says they meant. We've written separately on the intended-use doctrine, because that's where most of the movement in this area happens.

The compact way to hold it: the vial and the website are evaluated as one document.

Where "Research Use Only" Fits — and Where FDA Says It Stops

A research-use-only statement is a claim about intended use. It works when it's accurate, and it stops working when the material around it says something else.

Start with the affirmative case, because it's real. For material supplied to qualified research purchasers, a research-use-only designation is the correct and expected description of what that material is — not a fig leaf over something else. Our companion pieces cover what RUO labeling actually requires and how a "not for human use" statement carries legal weight.

What the statement cannot do is override the rest of the record. In its guidance on in vitro diagnostic products labeled for research use, FDA takes a position worth reading closely: where the circumstances of distribution and use contradict the designation, the label is itself false or misleading and therefore misbranding under section 502(a). That inverts the intuition most people bring to the phrase: a disclaimer that misdescribes the product becomes the violation rather than the shield. The agency applies a totality-of-the-circumstances test, weighing promotional materials and website content, distribution channels and the kind of purchaser actually served, and direct customer communications.

You can watch that test run in the letters themselves. A footnote recurs across several, including the June 2026 letter to Wholesale Peptide: despite labeling marketing the products for research use only and not for human consumption, evidence from the product labeling, including the firm's website, established that the products were intended to be drugs for human use. In both that letter and the USApeptide.com letter, the deciding evidence was ordinary product-page copy describing effects on named medical conditions.

The honest reading is that the phrase was never meant to be a magic incantation. It's one statement, weighed against every other statement a company makes.

Unapproved New Drug: The Third Finding That Travels Alongside

Readers skimming agency letters often see three findings and assume they are one claim stated three ways. They aren't.

A "new drug" under section 201(p) is one not generally recognized among qualified experts as safe and effective for use under the conditions prescribed, recommended, or suggested in its labeling, and section 505(a) requires FDA approval before such a product may enter interstate commerce. That's a question about regulatory status, not about material quality or label accuracy.

An important corollary: an FDA-approved product containing the same active compound confers nothing on anyone else's material. Approval attaches to the application, not the molecule — research-grade material is not equivalent to the FDA-approved pharmaceutical that shares its name, and the agency has said so directly.

The jurisdictional hook is interstate commerce as defined at section 201(b) — broad enough that ingredients, packaging, or shipping crossing a state line brings a product inside the statute. So three findings together are answering three questions: is it approved, is the material sound, and do the words tell the truth?

Frequently Asked Questions

What is the difference between misbranded and adulterated under the FDCA?

Adulteration is a finding about the material: its identity, purity, strength, or the conditions under which it was made. Misbranding is a finding about the words — what the labeling says, fails to say, or implies. FDA's guidance puts it plainly: adulteration means a product is unsafe or not what its composition is represented to be; misbranding means it has not been labeled properly. For drugs, the two live in adjacent sections, 501 and 502.

Can the same product be both misbranded and adulterated?

Yes, and in enforcement practice it frequently is. The two findings are independent, which carries a consequence worth internalizing: correcting a manufacturing deficiency does nothing for a labeling deficiency, and rewriting a label does nothing for a manufacturing problem. Each is addressed on its own terms.

Does a "research use only" statement make a product exempt from the FDCA?

No. FDA reads the statement as a claim about intended use that has to be accurate, not as an exemption. Its guidance on research-use-only in vitro diagnostic products says that where the circumstances of distribution contradict the label, the label itself is false or misleading and therefore misbranding under section 502(a). Several agency letters carry a footnote noting that despite research-use-only and not-for-human-consumption statements, the surrounding website copy established the products were intended as drugs for human use.

Why does FDA consider a website to be labeling?

Because the statutory definition is broad by design. Labeling covers all written, printed, or graphic matter on a product, on its containers or wrappers, or accompanying it — and FDA reads "accompanying" functionally rather than requiring physical attachment. That is why product pages, specification sheets, and marketing copy get quoted back to companies as labeling.

Is an unapproved new drug finding the same as misbranding?

No — it is a separate finding under a separate section, though the two appear together often enough to blur. A product is a new drug under section 201(p) if it is not generally recognized among qualified experts as safe and effective for the conditions suggested in its labeling, and section 505(a) requires approval before it enters interstate commerce. One letter can allege both, because they answer different questions.

The Bottom Line

Adulterated is about the material. Misbranded is about the message. The two are defined in adjacent sections of the same statute and judged entirely independently.

That distinction is the first thing worth establishing when you pick up an FDA document, because it tells you what kind of allegation you're reading and what real remediation would look like. A composition finding points at a facility, a process, and a set of records. A labeling finding points at what a company has written, everywhere it has written it.

The vocabulary is stable; the application is not. Nearly all of the live argument sits in how intended use gets determined, which makes the intended-use doctrine the natural next read.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.